SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS

Title:

SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS

Document Type and Number:

WIPO Patent Application WO/2016/081692

Kind Code:

A3

Abstract:

The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Inventors:

BLUM CHARLES A (US)
CALDWELL RICHARD DANA (US)
CASAUBON REBECCA (US)
DISCH JEREMY S (US)
FOX RYAN MICHAEL (US)
KOPPETSCH KARSTEN (US)
MILLER WILLIAM HENRY (US)
NG PUI YEE (US)
OALMANN CHRISTOPHER (US)
PERNI ROBERT B (US)
SZCZEPANKIEWICZ BRUCE G (US)
WHITE BRIAN H (US)

Application Number:

PCT/US2015/061501

Publication Date:

August 11, 2016

Filing Date:

November 19, 2015

Export Citation:

Click for automatic bibliography generation Help

Assignee:

GLAXOSMITHKLINE LLC (US)

International Classes:

C07D471/04; C07D513/18

Domestic Patent References:

WO2006094248A1

2006-09-08

Foreign References:

US20120252780A1	2012-10-04
US20110306609A1	2011-12-15
US20110046110A1	2011-02-24
US20140288052A1	2014-09-25

Other References: